DBV shares are crushed — while rival Aimmune soars — after PhIII flop for peanut allergy med
A couple of years ago, Paris-based DBV Technologies $DBVT set aside $95 million from an offering for its Phase III trial of a new therapy for peanut allergies.
On Friday, after the US market closed, DBV announced that the Phase III flopped, with their treatment unable to mark a statistically significant separation from a placebo arm as defined by the trial protocol. But the French biotech adds that they aren’t letting a primary endpoint failure stop them from filing a new drug application with the FDA in any case.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters